Research News on Chemotherapy
-
Giving Chemo and Radiation Therapy at Same Time Offers Same Benefits as Sequential Timing
In a study of women who'd been diagnosed with early breast cancer, local recurrence happened 35% less often in those who were treated with chemotherapy and radiation at the same time rather than sequentially (one after the other).
-
Experimental T-DM1 May Help Treat Advanced-Stage, HER2-Positive Disease
In a preliminary study, women with HER2-positive locally advanced or metastatic breast cancer treated with the targeted therapy T-DM1 lived longer without the cancer showing signs of progression compared to similar women who received a standard treatment combination of Herceptin (chemical name: trastuzumab) and Taxotere (chemical name: docetaxel).
-
“Personality” of Cancer Affects Recurrence Risk After Lumpectomy, Not When Chemo is Given
A study has found that cancer characteristics, not the timing of chemotherapy, affect the risk of recurrence in women diagnosed with early-stage breast cancer who had lumpectomy.
-
Most Women with Early-Stage Breast Cancer Benefit from Treatments After Surgery
Research suggests that that most women diagnosed with early-stage breast cancer are likely to benefit from chemotherapy, hormonal therapy, and/or targeted therapy after surgery.
-
Trelstar Reduces Risk of Chemo-Induced Menopause
Giving the medicine triptorelin during chemotherapy for breast cancer may hold off chemotherapy-induced menopause.
-
Experimental Genomic Test May Help Determine Need for Chemo Before Surgery
An experimental genomic test may help doctors figure out if invasive HER2-negative breast cancer will respond to chemotherapy before surgery.
-
FDA Approves Generic Taxotere
The FDA has approved a generic form of Taxotere, which may lower treatment costs.
-
Chemo, Hormonal Therapy May Increase Risk of Falling
Research suggests that women who get chemotherapy or hormonal therapy to treat early-stage breast cancer are more likely to fall than women the same age who don't get those treatments.
-
Halavan May Help Treat Metastatic Disease
Women diagnosed with metastatic breast cancer that didn't respond to other treatments who got Halavan lived 2 months longer than women who got supportive care or a standard metastatic cancer treatment.
-
Xeloda Doesn’t Seem to Reduce Recurrence Risk
A new study shows that the risk of recurrence is the same whether or not Xeloda was added to a standard adjuvant chemotherapy regimen for early-stage breast cancer with a high risk of recurrence.
